Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEGANT: elacestrant versus standard endocrine therapy in high-risk ER-positive/HER2-negative early breast cancer
2024-515445-42-00Phase 3Authorised
- Sponsor
- Stemline Therapeutics
- Start
- Mar 2025
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of elacestrant in breast cancer (2 arms), sponsored by Stemline Therapeutics. Primary endpoint: IBCFS. Planned start Mar 2025; status: authorised.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-515445-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515445-42-00.